bangaloremirror.indiatimes9d
Unexplained surge in Lichen Planus, stress, weak immunity may be causes
A significant increase in Lichen Planus cases has been observed post-COVID-19, with stress, weak immunity, and autoimmune ...
Lipella Pharma Shares Rise After Positive Trial Data for Oral Lichen Planus Treatment
Lipella Pharmaceuticals shares were up 37% to $4.18 after the company said it saw positive topline results from its Phase 2a dose-ranging trial examining LP-310, a liposomal-tacrolimus oral rinse ...
Nano Cap Lipella Pharmaceuticals Stock Jumps On Positive Trial Data In Patients With Sore Mouth Membranes
Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) shared topline an analysis of its Phase 2a dose-ranging trial of LP-310, a ...
Lipella Pharmaceuticals reports ‘positive’ results from Phase 2a LP-310 trial
Lipella Pharmaceuticals (LIPO) shared topline analysis of its Phase 2a multicenter dose-ranging trial examining LP-310, a liposomal-tacrolimus ...
Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus
LP-310 Treatment Demonstrates Clinically Meaningful Reductions in Pain, Ulceration, and Inflammation Across All Key Metrics ...
Pharmabiz13d
Lipella Pharma receives US FDA nod for expanded access programme for LP-310, an oral rinse formulation to treat oral lichen planus
Lipella Pharma receives US FDA nod for expanded access programme for LP-310, an oral rinse formulation to treat oral lichen planus: Pittsburgh Saturday, February 8, 2025, 09:00 Hr ...
BioSpace14d
Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus
Oral lichen planus is a chronic inflammatory condition affecting the mucous membranes inside the mouth, often causing burning pain, white patches, swollen tissue and open sores. The condition impacts ...
The Globe and Mail15d
Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus
Oral lichen planus is a chronic inflammatory condition affecting the mucous membranes inside the mouth, often causing burning pain, white patches, swollen tissue and open sores. The condition ...
Finanznachrichten15d
Lipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus
Oral lichen planus is a chronic inflammatory condition affecting the mucous membranes inside the mouth, often causing burning pain, white patches, swollen tissue and open sores. The condition impacts ...
FDA approves Lipella's oral treatment access program
PITTSBURGH - Lipella Pharmaceuticals Inc. (NASDAQ:LIPO), a biotech firm specializing in novel therapies for medical conditions lacking adequate treatments, has received FDA approval for an Expanded ...